Provided by Tiger Trade Technology Pte. Ltd.

SIHUAN PHARM

0.780
-0.040-4.88%
Volume:40.45M
Turnover:31.99M
Market Cap:7.11B
PE:33.99
High:0.825
Open:0.820
Low:0.780
Close:0.820
52wk High:1.896
52wk Low:0.750
Shares:9.12B
HK Float Shares:9.12B
Volume Ratio:0.57
T/O Rate:0.44%
Dividend:0.02
Dividend Rate:2.79%
EPS(LYR):0.023
ROE:5.57%
ROA:2.73%
PB:0.99
PE(LYR):33.99
PS:2.32

Loading ...

Hong Kong Stock Market Moves: SIHUAN PHARM Surges Over 4% as First-Half Net Profit Expected to Jump at Least 217.2% Year-on-Year, with Medical Aesthetics Business Maintaining Steady Growth

Stock News
·
Jul 27

Sihuan Pharmaceutical Expects H1 Profit to Soar At Least 217%

MT Newswires Live
·
Jul 27

Sihuan Pharmaceutical Shifts Bermuda Registered Office and Registrar to New Hamilton Address

Bulletin Express
·
Jul 27

SIHUAN PHARM Predicts First-Half Net Profit Surge of Over 217.2%

Stock News
·
Jul 27

Sihuan Pharma - Sees Hy Net Profit of not Less than Rmb210 Mln

THOMSON REUTERS
·
Jul 27

Sihuan Pharma - Expects H1 Revenue of at Least Rmb1,140 Mln and Net Profit of at Least Rmb210 Mln

THOMSON REUTERS
·
Jul 27

Xuanzhu Biopharma Ordered to Pay RMB 9.33 Million in Cietac Arbitration Award

Reuters
·
Jul 19

SIHUAN PHARM Shares Surge Over 12% in Early Trading Following Publication of Key Clinical Study

Stock News
·
Jul 14

Sihuan Pharma Says NMPA Accepts NDA for Anaprazole Sodium for Reflux Esophagitis

Reuters
·
Jul 06

Sihuan Pharmaceutical Holdings Group (SEHK:460) Following Phase III Trial Progress Is The Stock Too Pricey

Simply Wall St.
·
Jul 03

Sihuan Pharmaceutical Unit's Reflux Esophagitis Drug Application Accepted in China

MT Newswires Live
·
Jun 30

NMPA Accepts Sihuan Pharmaceutical Subsidiary Xuanzhu Biopharm’s NDA for Anaprazole Sodium in Reflux Esophagitis

Bulletin Express
·
Jun 30

Xuanzhu Biopharma Says NMPA Accepts NDA for Anaprazole Sodium in Reflux Esophagitis

Reuters
·
Jun 30

Sihuan Pharmaceutical AGM Clears All Resolutions; Final Dividend Set at HK1.09 Cents per Share

Bulletin Express
·
Jun 26

Sihuan Pharmaceutical Shareholders Approve RMB 0.96 Cent Final Dividend for 2025

Reuters
·
Jun 26

Sihuan Pharmaceutical launches Phase III trial of Anaprazole Sodium for Helicobacter pylori eradication

Bulletin Express
·
Jun 22

Xuanzhu Biopharma enrolls first patient in Phase III trial of anaprazole sodium for H. pylori eradication

Reuters
·
Jun 21

Xuanzhu Biopharmaceutical files director list with Hong Kong Stock Exchange

Reuters
·
Jun 18

Xuanzhu Biopharma names Yue Xin employee representative director after election

Reuters
·
Jun 18

SIHUAN PHARM Purchases 5 Million Shares for Incentive Scheme

Stock News
·
Jun 08